MA28329A1 - Formes cristallines de {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]pyridin -3-yl}-(2-chlorophenyl)-methanone. - Google Patents

Formes cristallines de {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]pyridin -3-yl}-(2-chlorophenyl)-methanone.

Info

Publication number
MA28329A1
MA28329A1 MA29043A MA29043A MA28329A1 MA 28329 A1 MA28329 A1 MA 28329A1 MA 29043 A MA29043 A MA 29043A MA 29043 A MA29043 A MA 29043A MA 28329 A1 MA28329 A1 MA 28329A1
Authority
MA
Morocco
Prior art keywords
pyridin
methanone
triazol
chlorophenyl
crystalline forms
Prior art date
Application number
MA29043A
Other languages
English (en)
Inventor
Alfio Borghese
David Scott Coffey
Pamela Kaye Footman
Steven Wayne Pedersen
Susan Marie Reutzel-Edens
Shella Lenyonga Tameze
Carsten Timpe
Carsten Weber
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA28329A1 publication Critical patent/MA28329A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention propose de nouvelles formes cristallines de la {2-[1-(3,5-bistrifluorométhylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophényl)-méthanone, des compositions de celles-ci, des intermédiaires de celles-ci, des procédés pour leur utilisation, des procédés pour leur préparation, et des procédés de préparation des intermédiaires.
MA29043A 2003-10-24 2006-05-22 Formes cristallines de {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]pyridin -3-yl}-(2-chlorophenyl)-methanone. MA28329A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24

Publications (1)

Publication Number Publication Date
MA28329A1 true MA28329A1 (fr) 2006-12-01

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29043A MA28329A1 (fr) 2003-10-24 2006-05-22 Formes cristallines de {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]pyridin -3-yl}-(2-chlorophenyl)-methanone.

Country Status (28)

Country Link
US (1) US7381826B2 (fr)
JP (1) JP4959336B2 (fr)
KR (1) KR100848407B1 (fr)
CN (1) CN1863791B (fr)
AR (1) AR046131A1 (fr)
AT (1) ATE462700T1 (fr)
AU (1) AU2004285855B8 (fr)
BR (1) BRPI0415010B8 (fr)
CA (1) CA2542140C (fr)
CL (2) CL2009001310A1 (fr)
CR (1) CR8353A (fr)
DE (1) DE602004026333D1 (fr)
DK (1) DK1675846T3 (fr)
EA (1) EA008881B1 (fr)
EC (1) ECSP066517A (fr)
ES (1) ES2340772T3 (fr)
HR (1) HRP20100207T1 (fr)
IL (1) IL174926A0 (fr)
MA (1) MA28329A1 (fr)
MY (1) MY157375A (fr)
NO (1) NO335090B1 (fr)
NZ (2) NZ545917A (fr)
PE (1) PE20050481A1 (fr)
PT (1) PT1675846E (fr)
TW (1) TW200524906A (fr)
UA (1) UA82901C2 (fr)
WO (1) WO2005042515A1 (fr)
ZA (1) ZA200603234B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006636A (es) * 2006-12-20 2009-06-30 Lilly Co Eli Nuevos intermediarios y procesos utiles en la rpeparacion de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]tr iazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona.
WO2009075778A2 (fr) * 2007-12-06 2009-06-18 The Regents Of The University Of California Inhibiteurs non peptidiques de la cruazïne
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
AU2016226006B2 (en) 2015-03-04 2021-03-04 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10287287B2 (en) 2015-08-17 2019-05-14 Eli Lilly And Company Process development of a pyridine-containing NK-1 receptor antagonist
BR112020004964A2 (pt) 2017-09-13 2020-09-15 Vanda Pharmaceuticals Inc. método que consiste em administrar uma quantidade de tradipitant eficaz, aperfeiçoamento, método aperfeiçoado para tratar um paciente que sofre de prurido ou dermatite atópica com tradipitant, e, métodos para tratar um paciente com prurido ou dermatite atópica, para selecionar e para determinar uma dosagem de tradipitant eficaz, para determinar que um paciente tem probabilidade de responder ao tratamento de dermatite atópica com tradipitant e para identificar um paciente.
EP3710000A1 (fr) * 2017-11-17 2020-09-23 Vanda Pharmaceuticals Inc. Méthode de traitement de maladies gastro-intestinales avec du tradipitant
CN112218636A (zh) 2018-06-08 2021-01-12 万达制药公司 使用川地匹坦进行治疗的方法
JP7468964B2 (ja) * 2018-09-28 2024-04-16 バンダ・ファーマシューティカルズ・インコーポレイテッド 動揺病におけるトラジピタントの使用
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
EP3890735A1 (fr) * 2018-12-03 2021-10-13 Vanda Pharmaceuticals Inc. Méthode de traitement avec le tradipitant
EP4110335A1 (fr) 2020-02-25 2023-01-04 Vanda Pharmaceuticals Inc. Traitement amélioré de dermatite atopique au moyen de tradipitant
JP2023520369A (ja) 2020-03-26 2023-05-17 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (fr) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Traitement de l'accommodation gastrique avec du tradipitant
EP4395778A1 (fr) 2021-08-31 2024-07-10 Vanda Pharmaceuticals Inc. Traitement d'une infection des voies respiratoires inférieures avec du tradipitant
WO2024138040A1 (fr) 2022-12-21 2024-06-27 Vanda Pharmaceuticals Inc. Méthodes de traitement par tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
ATE333879T1 (de) * 1996-10-07 2006-08-15 Merck Sharp & Dohme Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
BR0013551A (pt) * 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
CA2388202A1 (fr) * 1999-10-29 2001-05-10 Merck & Co., Inc. Forme polymorphe d'un antagoniste de recepteur de tachykinine
US20020044971A1 (en) 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
PE20040600A1 (es) 2002-04-26 2004-09-15 Lilly Co Eli Derivados de triazol como antagonistas del receptor de taquicinina

Also Published As

Publication number Publication date
BRPI0415010A (pt) 2006-11-07
ATE462700T1 (de) 2010-04-15
NO335090B1 (no) 2014-09-08
WO2005042515A1 (fr) 2005-05-12
ZA200603234B (en) 2007-07-25
BRPI0415010B8 (pt) 2021-05-25
NZ580480A (en) 2010-02-26
CL2009001310A1 (es) 2009-12-04
AR046131A1 (es) 2005-11-23
CA2542140A1 (fr) 2005-05-12
CN1863791A (zh) 2006-11-15
AU2004285855B8 (en) 2011-04-28
DK1675846T3 (da) 2010-05-31
KR100848407B1 (ko) 2008-07-28
HRP20100207T1 (hr) 2010-05-31
AU2004285855B2 (en) 2010-12-23
KR20060061388A (ko) 2006-06-07
BRPI0415010B1 (pt) 2019-07-09
BRPI0415010A8 (pt) 2018-05-08
ES2340772T3 (es) 2010-06-09
JP2007509143A (ja) 2007-04-12
EA008881B1 (ru) 2007-08-31
EA200600829A1 (ru) 2006-08-25
US7381826B2 (en) 2008-06-03
NO20062371L (no) 2006-05-24
AU2004285855A1 (en) 2005-05-12
CA2542140C (fr) 2012-05-29
IL174926A0 (en) 2006-08-20
CR8353A (es) 2006-06-06
MY157375A (en) 2016-06-15
JP4959336B2 (ja) 2012-06-20
PT1675846E (pt) 2010-04-20
UA82901C2 (en) 2008-05-26
TW200524906A (en) 2005-08-01
NZ545917A (en) 2009-11-27
PE20050481A1 (es) 2005-09-20
CN1863791B (zh) 2011-12-07
DE602004026333D1 (de) 2010-05-12
US20070078166A1 (en) 2007-04-05
ECSP066517A (es) 2006-10-10
CL2009001311A1 (es) 2009-10-02

Similar Documents

Publication Publication Date Title
MA28329A1 (fr) Formes cristallines de {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]pyridin -3-yl}-(2-chlorophenyl)-methanone.
NO20161012A1 (no) Farmasøytisk sammensetning omfattende polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-1,6-dion
TR200201568T2 (tr) İkame edilmiş imidazol nöropeptid Y Y5 reseptörü antagonistleri.
PT969819E (pt) Nova forma cristalina de omeprazole
WO2002098856A3 (fr) Antagonistes du recepteur d'adenosine diphosphate plaquettaire
CA2536870A1 (fr) Composes de phenyle ou de pyridyle amide utiles comme antagonistes de la prostaglandine e2
TW200504015A (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2003086303A3 (fr) Agonistes de recepteur active frx (farnesoid x receptor)
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
DE60218703D1 (de) (-)-1-(3,4-dichlorphenyl)-3-azabicyclo ä3.1.0ühexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer
MA29791B1 (fr) Composes therapeutiques.
TR200102138T2 (tr) (S)-Omeprazolün potasyum tuzu.
MX2007003471A (es) Nueva forma cristalina de clorhidrato de (3-cian-1h-indol-7-il)-[4 -(4-fluorofenetil)-piperazin-1-il]-metanona.
UA83648C2 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
HRP20020973A2 (en) Process for the synthesis of (2r,2-alpha-r,3a)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1,4-oxazine
NO20045001L (no) Fremgangsmate for fremstilling av 5-[[2(R)-[1(R)-[3,5-bis(trifluormetyl)fenyl]etoksy]-3(S)-(4-fluorfenyl)-4-morfolinyl]metyl]-1,2-dihydro-3H-1,2,4-triazol-3-on
BG107046A (en) Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
IL155706A0 (en) Process for the preparation of (r)-5-(2-benzenesulfonylethyl)-3-(n-methylpyrrolidin-2-ylmethyl)-1h-indole
HU0002147D0 (en) Process of ntc-2000 code-number for producing compounds having antiplasmid activity and pharmaceutical compositions containind them
PL1675846T3 (pl) Nowe krystaliczne postacie {2-[1-(3,5-bis-trifluoro-metylobenzylo)-5-pirydyn-4-ylo-1H-[1,2,3]triazol-4-ilo]-pirydyn-3-ylo}-(2-chlorofenylo)metanonu
SE0302956D0 (sv) Chemical compounds
NZ595125A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
SG145572A1 (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
MY118724A (en) New crystalline form of omeprazole
YU32301A (sh) Novi kristalni oblik omeprazola